Kiniksa Pharmaceuticals International, plc $KNSA Stock Position Reduced by Knights of Columbus Asset Advisors LLC

Key Points

• Knights of Columbus Asset Advisors LLC reduced its position in Kiniksa Pharmaceuticals by 47.9% during the 2nd quarter, selling 30,002 shares and leaving them with 32,622 shares valued at approximately $903,000.
• Wall Street analysts have issued a consensus rating of “Moderate Buy” for Kiniksa Pharmaceuticals, with an average target price of $44.29, indicating continued positive outlook despite some recent downgrades.
• Insider trading activity showed significant selling, with the director and COO selling over 200,000 shares combined, raising concerns about insider confidence in the company.

Knights of Columbus Asset Advisors LLC cut its position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 47.9% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 32,622 shares of the company's stock after selling 30,002 shares during the quarter. Knights of Columbus Asset Advisors LLC's holdings in Kiniksa Pharmaceuticals International were worth $903,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the company. Robeco Institutional Asset Management B.V. acquired a new position in shares of Kiniksa Pharmaceuticals International during the 2nd quarter valued at $233,000. Toth Financial Advisory Corp acquired a new position in shares of Kiniksa Pharmaceuticals International in the 2nd quarter worth $296,000. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Kiniksa Pharmaceuticals International by 13.6% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 15,410 shares of the company's stock worth $430,000 after acquiring an additional 1,846 shares during the last quarter. Pallas Capital Advisors LLC acquired a new position in shares of Kiniksa Pharmaceuticals International in the 2nd quarter worth $236,000. Finally, Voya Investment Management LLC grew its holdings in shares of Kiniksa Pharmaceuticals International by 54.4% in the 1st quarter. Voya Investment Management LLC now owns 30,866 shares of the company's stock worth $686,000 after acquiring an additional 10,878 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Wells Fargo & Company lifted their target price on Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an "overweight" rating in a report on Thursday, September 25th. Wedbush restated an "outperform" rating and issued a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st. Weiss Ratings restated a "hold (c)" rating on shares of Kiniksa Pharmaceuticals International in a report on Saturday, September 27th. TD Cowen assumed coverage on Kiniksa Pharmaceuticals International in a report on Monday, September 29th. They issued a "buy" rating and a $60.00 target price on the stock. Finally, Wall Street Zen cut Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a report on Friday, October 3rd. Seven analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $44.29.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In related news, Director Thomas Malley sold 78,233 shares of Kiniksa Pharmaceuticals International stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $33.09, for a total transaction of $2,588,729.97. Following the completion of the sale, the director owned 12,546 shares of the company's stock, valued at approximately $415,147.14. This trade represents a 86.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Eben Tessari sold 138,614 shares of Kiniksa Pharmaceuticals International stock in a transaction on Tuesday, August 5th. The shares were sold at an average price of $33.20, for a total value of $4,601,984.80. Following the sale, the chief operating officer directly owned 49,915 shares of the company's stock, valued at approximately $1,657,178. The trade was a 73.52% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 603,371 shares of company stock valued at $20,434,869 in the last ninety days. Company insiders own 53.48% of the company's stock.

Kiniksa Pharmaceuticals International Trading Down 0.4%

Shares of KNSA stock opened at $38.12 on Wednesday. Kiniksa Pharmaceuticals International, plc has a 1-year low of $17.82 and a 1-year high of $39.12. The company has a market capitalization of $2.83 billion, a price-to-earnings ratio of 953.24 and a beta of 0.16. The stock's fifty day simple moving average is $34.87 and its 200-day simple moving average is $28.91.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, beating analysts' consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%.The business had revenue of $156.80 million for the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

Want to see what other hedge funds are holding KNSA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.